Chris Viehbacher, CEO of Boston biotech giant Biogen, believes that greater Boston has the premier gathering of scientists in medicine in the world. Addressing today’s gathering of the Boston Chamber of Commerce, he claimed that nations contend commercially based on brain power and that America is in the lead when it comes to life sciences, pointing particularly to the concentration of talent in Kendall Square, adjacent MIT and nearby Harvard, with Northeastern just across the river (he is a Northeastern Trustee. And it just so happens that Biogen’s new building in Kendall Square is coming on line, as Biogen turns 50 years old).
Some interesting take-aways:
Medicine is expensive but ability to profit from innovation lasts only as long as the patent rights; patents issue before there is a viable commercial product so the profit time line is abbreviated. He prefers to acquire early stage companies as they are less costly if far away from commercialization, but that also tends to lead to more disappointments.
Boston is really expensive and attracting talent is thus hindered; transportation poor, housing dear. But people are attracted here as the hub of cutting edge innovation. Biogen manufactures in North Carolina, it is true, but the real innovation is here.
No surprise that AI is useful; two areas are finding proper people for clinical trials (seems that is time-consuming and difficult) and speeding up research on molecules. Speed, again, is vital as an economic matter; the faster you move, the less time gets burned off patent life with no marketable product.
Immigration is important to the Boston area ecosystem in life science; look at who has earned patents? It is key to continuation of the unique Boston primacy in innovation. (No mention of tension with the Federal administration–except perhaps implicitly.)
Noting the current vacancy rate of lab space in the Boston area, he warned that more innovation is coming: “Don’t refit those buildings to condos just yet.”
An insight into how one must look at developing bio products: stop thinking about symptoms as something to understand and cure; look for the clues for the cause of those symptoms and treat the causes. Often one cause resonates in several areas of the body; in what area is the immune system failing?
His company is working on many new products at once, having ten now in Stage 3 testing. Some, many will fail. He analogizes this approach to the manner in which venture capital operates: promising investment very often will fail to work out, it is necessary to spread your investments in many so that you will hit the small number of successes, thus reaching a total net positive return. (I find that analysis fascinating today: there is current literature explaining Crypto, prediction markets and intense betting on sports apps as simply mirroring what VCs do–you cannot see a certain path of success so your bets need to be spread out. I wonder if Biogen has some bets down on the World Series…..)